G7879
D-Glucose 6-phosphate sodium salt
≥98% (HPLC)
Synonym(s):
D(+)-Glucopyranose 6-phosphate sodium salt, G-6-P Na, Robison ester
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C6H12NaO9P
CAS Number:
Molecular Weight:
282.12
UNSPSC Code:
12352201
NACRES:
NA.25
PubChem Substance ID:
EC Number:
258-921-0
Beilstein/REAXYS Number:
5787568
MDL number:
biological source
synthetic (organic)
Quality Level
assay
≥98% (HPLC)
form
crystalline
technique(s)
HPLC: suitable
color
white
useful pH range
4.0-5.0
mp
204 °C (dec.) (lit.)
solubility
water: 50 mg/mL, clear, colorless to very faintly yellow
cation traces
Na: 6.1-10.2% (anhydrous)
application(s)
advanced drug delivery
storage temp.
room temp
SMILES string
[Na+].O[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H](O)[C@H]1O
InChI
1S/C6H13O9P.Na/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8;/h2-10H,1H2,(H2,11,12,13);/q;+1/p-1/t2-,3-,4+,5-,6-;/m1./s1
InChI key
ZALKNDISPIVVKC-WYRLRVFGSA-M
Application
D-glucose-6-phosphate sodium can be used as an energy source for Mycobacterium tuberculosis.
Biochem/physiol Actions
In cells, D-glucose 6-phosphate (G6P) is generated when glucose is phosphorylated by hexokinase or glucokinase or by the conversion of glucose-1-phosphate by phosphoglucomutase during glycogenolysis. G6P lies at the beginning of both glycolysis and the pentose phosphate pathways. It also can be stored as glycogen when blood glucose levels are high.
Other Notes
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Disclaimer
Non-hygroscopic, and very stable to atmospheric moisture at room temperature, unlike the disodium salt.
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Iain J Abbott et al.
The Journal of antimicrobial chemotherapy, 75(4), 988-996 (2019-12-25)
To assess the antibacterial effects of a single 3 g oral fosfomycin dose on Escherichia coli and Klebsiella pneumoniae clinical isolates within a dynamic bladder infection model. An in vitro model simulating dynamic urinary fosfomycin concentrations was used. Target fosfomycin exposure
Iain J Abbott et al.
Antimicrobial agents and chemotherapy, 64(6) (2020-04-08)
There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against E. faecalis and E.
Iain J Abbott et al.
Antimicrobial agents and chemotherapy, 64(3) (2020-01-08)
Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and any benefit of giving multiple